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Editorial
Patient Safety Requires a New Way
to Publish Clinical Trials
Richard Smith*, Ian Roberts
The way medical journals publish the
results of clinical trials has become a
serious threat to public health. You may
ﬁnd this assertion shocking and
counterintuitive, but we hope that by
theendof this short article youwill agree
and will join us in arguing for the better
way of making medical information
publicly available that we outline.
Journals Are Publishing Partial
and Biased Reports from Trials
The publication of a clinical trial marks
the birth of new medical knowledge, and
medical editors are the midwives.
Although most editors would like to
meet expectant researchers shortly after
a clinical trial’s conception (or even
before), to ﬁnd out who the parents are
and to ensure that the trial receives high-
quality antenatal care, more often than
not labouring researchers arrive at their
ofﬁces heavily pregnant with results that
require immediate, fast-track delivery.
Some trials are deposited on the editor’s
doorstep, so that it is hard to tell who the
parents are. Unfortunately, many trialists
have become eugenicists, highly adept in
the selective breeding of favourable
results [1]. They do this to serve the
masters who pay them, often the
pharmaceutical industry. Their masters
ﬁnd favourable results useful for
marketing [2]; the trialists have their
pockets l ined and their careers
advanced. The editors have newsworthy
trials to publish, and the owners of the
journal enjoy the substantial proﬁts that
come from selling reprints of the trials.
The losers are the trial participants whose
contribution to research is wasted, the
patients who must swallow the drugs
despite the distorted evidence, and the
public who must pay for the drugs [3].
A Better Way
The new model we propose would start
with posting a systematic review of the
existing trial evidence on the Web to
show what is already known about the
effectiveness of a particular treatment
and what further research is needed.
If there is uncertainty about the
effectiveness of the treatment, such that
a further trial is needed, a new trial would
be registered and the trial protocol would
also be posted on the Web. Everybody
with any involvement in the trial would
be listed with their contribution
explained, abolishing the current need
for ‘‘paternity testing’’ of published trials.
At any point, observers—be they patients,
researchers, clinicians, editors, or anyone
else—would be able to comment online
about the interpretation of the systematic
review’s data, the importance of the trial
question, or the reliability of its methods.
In this new world, there
would be no
investigator-driven and
thus potentially biased
post hoc analysis, no
discussion sections and
thus no spinning of the
results, and no peer
review of trial reports.
The statistical analysis would be pre-
speciﬁed by uploading the program-
ming code (in Stata or SAS, for
instance) and a speciﬁcation for the
ﬁnal dataset. The protocol would in-
clude detailed speciﬁcations of any
subgroup analyses, giving their biologi-
cal rationale and the anticipated direc-
tion of effects [4]. The analysis could
also incorporate routine statistical tests
to check for the presence of data
fabrication and falsiﬁcation [5,6]. When
data collection in the new trial is
completed, the entire dataset would
be uploaded and the analyses would be
run. There would be no investigator
commentary on the trial data. The
systematic review would be updated to
include the new trial.
PLoS Clinical Trials is a step in the
direction we are proposing, and may
perhaps in the long run form a platform
for the full system. The role of traditional
medical journals would be to comment
and debate on all the stages of the process
rather than publish the trial results [2].
For practitioners, they might also report
on systematic reviews—because, it is
unlikely that many practitioners will
access full datasets on the Web. They
should report on reviews not individual
trials to avoid presenting their readers
with only part of the evidence. (There will
sometimes be systematic reviews that
include only one trial.) It will be
important, however, for journals to do
all they can to avoid bias in their
reporting and for practitioners to
understand that no matter how hard
journals try to be unbiased they will
never succeed entirely.
A new model is needed because the
current one is in tatters: clinical trial
results are being manipulated. What
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matters is the totality of the relevant trial
evidence. By publishing individual
clinical trials ad hoc, the medical
journals provide a mechanism that can
be subverted by funding bodies and
researchers with an interest in getting
particular trial results.
The Current Model of Publishing
Trials Is in Tatters
The most common eugenic techniques
are selective reporting and the creative
use of probability [1]. There may be late
termination of trials with unfavourable
results, such that they are withheld from
the publication process , or else
unfavourable ﬁndings may be surgically
excised from the trial publication [3,7–9].
On the other hand, trials with favourable
results may be published many times
(cloning), and then intensively marketed
t o e n s u r e t h e y a r e n o t i c e d .
Methodologists believe these are the
most common and the most important
forms of misconduct in clinical trials [1].
Nevertheless, although editors will not
hesitate to name and shame if they
suspect data falsiﬁcation, which is
comparatively rare, they seem to be
relaxed about selective reporting. They
pounce on the shoplifting bag ladies but
turn a blind eye to white collar crime.
Posting trial protocols on the Web
would allow open debate about the
importance, relevance, and quality of
the trial [10,11]. Indeed, proper peer
review of trial questions and methods
would be a better way of improving
medical research than peer reviewing
trial reports, especially when it is often
impossible to tell what information has
been omitted. Too many trials cover
issues that matter to drug companies
(showing that the 24th beta-blocker is
better in some way than the 23rd) rather
than answering questions that matter to
patients. When the trial is over, the full
dataset would be uploaded to accompany
the trial protocol. Pre-programmed
analyses would prevent deviation from
the protocol, suppression of results, and
any undue emphasis on post hoc
subgroup analyses [12,13]. Posting
full datasets could allow quicker
identiﬁcation of adverse effects and
more critical analysis of the raw data,
which may reduce the chances of fraud.
In this new world, there would be no
investigator-driven and thus potentially
biased post hoc analysis, no discussion
sections and thus no spinning of the
results, and no peer review of trial
reports since all this would have been
done at the protocol stage. The discussion
section of a scientiﬁc paper typically has
ﬁve functions: (1) to state the principal
ﬁndings, (2) to identify strengths and
weaknesses of the study, (3) to identify
strengths and weaknesses in relation to
other studies (there is good evidence that
most trials fail to do this), (4) to state the
meaning of the study, (5) and to identify
unanswered questions for future research
(M. Clarke, S. Hopewell, I. Chalmers,
unpublished communication) [14–16].
The ﬁrst is best summarised numerically
in the point estimates and conﬁdence
intervals; the second is determined by
trial design, which is evident from the
protocol; and the remainder are more
appropriate in the context of the relevant
systematic review. The discussion section
of a clinical trial is therefore redundant.
Posting on the Web the updated
systematic review would be more useful
for patients and clinicians and would
avoid the hyping of single trials. Ending
the publication of trials in journals would
reduce the manipulation, spin, and hype
that are now pervasive in medical
publishing. Restricting journals to
comment, debate, and digestion would
make them more readable and more
useful to patients and doctors alike.
Vested Interests Are a Barrier to
Change
These proposals should improve the
quantity and quality of information on
the effectiveness and safety of medical
treatments, and for this reason, they
should be welcomed. Not everyone will
agree. Drug companies are nervous about
posting protocols because they claim it
could give away competitive information.
But if all companies have to post their
protocols, there would be no comparative
disadvantage. It is the marketing
departments of companies that will be
most likely to object to the new way of
posting protocols and results. Hype will
be made much more difﬁcult, and market
advantage will be hard to achieve unless
companies have products that truly are
superior. Medical journals love the loot
and prestige that goes with publishing
clinical trials, and many would disappear
if trials were no longer published.
However, the writing is already on the
wall for traditional clinical trial
publication. Citation analysis already
shows that systematic reviews and meta-
analyses receive more citations than any
other study design [17]. This trend is
likely to continue. Researchers might be
reluctant to make available ‘‘their’’ raw
data out of fear that this will provide
ma te r i a l f o r t h e i r in t e l l e c tua l
‘‘competitors.’’ On the other hand, if
they want to maintain the respect of the
general public, in the context of several
widely publicised cases of medical fraud,
they will have to make datasets available
for statistical scrutiny [18].
Box 1. Problems with the Present
System of Publishing Trials
 There is too much emphasis on the results
of individual trials rather than the totality of
the evidence
 Trials are conducted and published without
a systematic review of existing evidence,
meaning that trials are conducted
unnecessarily or don’t address the most
important questions
 Trials often deviate considerably from
protocols, but readers of trial results don’t
know this
 Results are selectively published with
positive results emphasised or published
more than once, and negative results are
ignored
 Full results, including all side effects, are not
published
 Published trial results are usually favourable
to sponsors because of a wide variety of
methods of manipulation
 Methods of analysis are not clear, and post
hoc analyses are not presented as such
 Authorship of trials is unclear
 Introduction and discussion sections are
often little more than spin
 Trials favourable to sponsors are published
in major journals, and unfavourable trials
are not published at all or are published in
minor journals
Box 2. Our Proposed New System
 A systematic review is posted on the Web
 If a new trial is needed, it is registered and a
full protocol is devised in light of the
systematic review and posted on the Web
 Anybody can comment online on the
interpretation of the systematic review data,
the importance of the trial question, or the
reliability of its methods
 The statistical analysis would be pre-
specified and pre-programmed
 When data collection is completed, the
entire dataset would be uploaded and the
analyses run
 There would be no investigator
commentary on the trial data
 The systematic review would be updated
to include the new trial
 Journals would not publish trials but
rather commentaries and reports on
systematic reviews
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All change tends to be resisted,
and we’ve outlined reasons why drug
companies, researchers, and journals will
all oppose what we propose, and these are
the voices that are heard most loudly in
any debate over trials. Nevertheless, we
believe that our proposal will eventually
be implemented. The ‘‘platform will
begin to burn’’ as more evidence
emerges of patients being harmed by
the manipulation of trial results.
Governments and others who must pay
for hyped drugs will also join the debate
as they better understand how trial
ev idence i s be ing manipu la ted .
Eventually, governments will mandate
new ways to make the results of trials
available, just as they are already
mandating the registering of trials. “
Acknowledgments
We thank Iain Chalmers and Tony Brady
for helpful comments on earlier drafts of
the manuscript.
References
1. Al-Mazurka S, Roberts I, Marshall T, Evans S
(2005) The effect of scientiﬁc misconduct on
the results of clinical trials: A Delphi survey.
Contemp Clin Trials 26: 331–337.
2. Smith R (2005) Medical journals are an
extension of the marketing arm of
pharmaceutical companies. PLoS Med 2: e138.
DOI: 10.1371/journal.pmed.0020138
3. Chalmers I (1990) Underreporting research is
scientiﬁc misconduct. JAMA 263: 1405–1408.
4. Assmann SF, Pocock SJ, Enos LE, Kasten LE
(2000) Subgroup analyses and other (mis) uses
of baseline data in clinical trials. Lancet 355:
1064–1069.
5. Buyse M, George SL, Evans S, Geller NL,
Ranstam J, et al. (1999) The role of
biostatistics in the prevention, detection and
treatment of fraud in clinical trials. Stat Med
18: 3435–3451.
6. Al-Marzouki S, Evans S, Marshall T, Roberts I
(2005) Are these data real? Statistical methods
for the detection of data fabrication in clinical
trials. BMJ 331: 267–270.
7. Chan AW, Hro´bjartsson A, Haahr MT, Gøtzche
PC, Altman DG (2004) Empirical evidence for
selective reporting of outcomes in randomised
trials. JAMA 291: 2457–2465.
8. Chan AW, Krlezˇa-Jeric K, Schmid I, Altman DG
(2004) Outcome reporting bias in randomized
trials funded by the Canadian Institutes of
Health Research. CMAJ 171: 735–740.
9. Chan AW, Altman DG (2005) Identifying
outcome reporting bias in randomised trials
on PubMed: Review of publications and survey
of authors. BMJ 330: 753. DOI: 10.1136/
bmj.38356.424606.8F
10. Chalmers I, Altman DG (1999) How can
medical journals help prevent poor medical
research? Some opportunities presented by
electronic publishing. Lancet 353: 490–493.
11. Jones G, Abbasi K (2004) Trial protocols at the
BMJ. BMJ 329: 1360.
12. Rothwell PM (2005) Subgroup analysis in
randomised controlled trials: Importance,
indications and interpretation. Lancet 365:
176–186.
13. Cook DI, Gebeski VJ, Keech AC (2004)
Subgroup analyses in clinical trials. Med J Aust
180: 289–292.
14. Docherty M, Smith R (1999) The case for
structuring the discussion of scientiﬁc papers.
BMJ 318: 1224–1225.
15. Clarke M, Chalmers I (1998) Discussion
sections in reports of controlled trials
published in general medical journals: Islands
in search of continents? JAMA 280: 280–282.
16. Clarke M, Alderson P, Chalmers I (2002)
Discussion sections in the reports of
controlled trials published in General Medical
Journals. JAMA 287: 2799–2801.
17. Patsopoulos NA, Analatos AA, Ioannidis JP
(2005) Relative citation of various study
designs in the health sciences. JAMA 293:
2362–2366.
18. Fouche G (2006 January 16) Respected
Norwegian scientist faked study on oral
cancer. The Guardian. Available: http://
education.guardian.co.uk/higher/worldwide/
story/0,9959,1687477,00.html. Accessed 13
April 2006.
www.plosclinicaltrials.org May | 2006 | e60003
